Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review (2022)

Peer-Reviewed Study · Izcovich A, Peiris S, Ragusa M, Tortosa F, Rada G, Aldighieri S, Reveiz L · April 2022

Izcovich A et al., 2022-04: Systematic review of 29 randomized trials (5592 patients) showing that ivermectin's apparent benefits shrank or vanished once high-risk-of-bias trials were excluded.

Previous reports concluding important benefits associated with ivermectin are based on potentially biased results reported by studies with substantial methodological limitations.

Izcovich A et al., 2022-04: Systematic review of 29 randomized trials (5592 patients) showing that ivermectin's apparent benefits shrank or vanished once high-risk-of-bias trials were excluded. Systematic review and random-effects meta-analysis with GRADE, 29 RCTs, 5592 participants, searches of the L.OVE platform to 6 July 2021. Overall certainty very low to low suggested possible important benefits; after excluding trials rated high risk or 'some concerns', most estimates changed substantially, with no clear effect on improvement or viral clearance. No funding or conflict statement is carried in the PubMed record; the author group includes Pan American Health Organization staff. This is the methodological critique aimed at the positive meta-analyses. Study type: review.